Compounds > oxantel
Page last updated: 2024-12-10

oxantel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oxantel: oxyphenyl analog of pyrantel; RN given refers to (E)-isomer; synonym CP-14,445-16 refers to oxantel pamoate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281087
CHEMBL ID1240977
CHEBI ID135610
SCHEMBL ID43905
SCHEMBL ID555044
MeSH IDM0044456

Synonyms (30)

Synonym
36531-26-7
AC-12737
oxantel
CHEBI:135610
3-[(e)-2-(1-methyl-5,6-dihydro-4h-pyrimidin-2-yl)ethenyl]phenol
CHEMBL1240977
AKOS015961005
(e)-m-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)vinyl)phenol
94ajj30d9e ,
oxantelum [inn-latin]
phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl)-, (e)-
oxantel [inn:ban]
unii-94ajj30d9e
(e)-3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)vinyl)phenol
oxantelum
BRD-K66019333-096-01-2
oxantel [who-dd]
oxantel [inn]
oxantel [mi]
phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (e)-
SCHEMBL43905
SCHEMBL555044
(e)-3-(2-(1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)vinyl)phenol
DB13670
Q1227207
DTXSID601016597
gtpl10840
cp-14,445
CS-0086698
HY-124498

Research Excerpts

Overview

Oxantel is a cholinergic anthelmintic. It was first introduced for the treatment of whipworm, Trichuris, infections in children.

ExcerptReferenceRelevance
"Oxantel is a cholinergic anthelmintic that was first introduced for the treatment of whipworm, Trichuris, infections in children."( Oxantel is an N-type (methyridine and nicotine) agonist not an L-type (levamisole and pyrantel) agonist: classification of cholinergic anthelmintics in Ascaris.
Clark, CL; Martin, RJ; Robertson, AP; Trailovic, SM, 2004)		2.49

Treatment

ExcerptReferenceRelevance
"Oxantel treatment caused the downregulation of six P."( Oxantel disrupts polymicrobial biofilm development of periodontal pathogens.
Catmull, D; D'Cruze, T; Dashper, S; Hoffmann, B; Liu, SW; Mitchell, H; O'Brien-Simpson, N; Paolini, R; Reynolds, E; Walsh, K; Zhu, Y, 2014)		2.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
styrenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID510498Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in average number of microcolonies at 125 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510315Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as mean generation time at 31.25 uM2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510493Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in average number of microcolony area at 12.5 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510494Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in biovolume at 125 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510500Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as thickness of biofilm at 12.5 uM after 18 hrs by confocal laser scanning microscopy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510489Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in thickness of biofilm at 12.5 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510497Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in surface area of substratum occupied by cells at 125 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510312Antimicrobial activity against Porphyromonas gingivalis W502010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510319Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction of biofilm formation at 125 uM after 24 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510495Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in thickness of biofilm at 125 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510501Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as thickness of biofilm at 125 uM after 18 hrs by confocal laser scanning microscopy2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510488Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in biovolume at 12.5 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510490Antimicrobial activity against Porphyromonas gingivalis assessed as surface area/biovolume ratio at 12.5 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510316Antimicrobial activity against Porphyromonas gingivalis W50 assessed as mean generation time at 62.5 uM2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510496Antimicrobial activity against Porphyromonas gingivalis assessed as surface area/biovolume ratio at 125 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510499Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in average number of microcolony area at 125 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510317Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as mean generation time at 62.5 uM2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510313Antimicrobial activity against Porphyromonas gingivalis ATCC 332772010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510314Antimicrobial activity against Porphyromonas gingivalis W50 assessed as mean generation time at 31.25 uM2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510491Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in surface area of substratum occupied by cells at 12.5 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510318Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction of biofilm formation after 24 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510492Antimicrobial activity against Porphyromonas gingivalis assessed as reduction in average number of microcolonies at 12.5 uM after 18 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
AID510487Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction of biofilm formation at 0.1 uM after 24 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Inhibition of Porphyromonas gingivalis biofilm by oxantel.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (26.09)18.7374
1990's3 (13.04)18.2507
2000's5 (21.74)29.6817
2010's7 (30.43)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.25 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index66.52 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (45.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other23 (88.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Efficacy of 5 Anthelmintic Regimes Against T. Trichiura Infections in Schoolchildren in Jimma, Ethiopia [NCT01327469]Phase 42,250 participants (Actual)Interventional2010-12-31Completed
Different Drug Combinations Against Hookworm Infection in School-aged Children in the Lao People's Democratic Republic, a Single Blind, Randomised Controlled Trial [NCT03278431]Phase 4420 participants (Actual)Interventional2017-09-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
choline
[no description available]		2.3110cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
malic acid
malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.		2102-hydroxydicarboxylic acid;
C4-dicarboxylic acid		food acidity regulator;
fundamental metabolite
albendazole
[no description available]		2.1710aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		7.6730aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.0510C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
praziquantel
azinox: Russian drug		9.1531isoquinolines
thiabendazole
Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate		2.7301,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		2.0510amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
thiazoles
[no description available]		2101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		7.41206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
methyridine
methyridine: veterinary anthelmintic & nematocide; minor descriptor (75-85); on-line & Index Medicus search PYRIDINES (75-85)		7.4120pyridines
nitroscanate
[no description available]		2.1710
epsiprantel
epsiprantel: RN given refers to cpd without isomeric designation		2.1710
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		7.42203-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
pyrantel
Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.		5.882311,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes		antinematodal drug
pyrantel pamoate
Pyrantel Pamoate: Broad spectrum antinematodal anthelmintic used also in veterinary medicine.		4.6261organic molecular entity
oxantel pamoate
[no description available]		2.1710naphthoic acid
morantel
Morantel: Antinematodal agent used mainly for livestock.		3.4270
fumarates
Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)		210butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite
dextrothyroxine
[no description available]		210
ConditionIndicatedRelationship StrengthStudiesTrials
Pericementitis
[description not available]		02.7730
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		02.7730
Trichocephaliasis
[description not available]		03.2260
Trichuriasis
Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.		03.2260
Bunostomiasis
[description not available]		02.1710
Hookworm Infections
Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.		02.1710
Bertielliasis
[description not available]		03.8721
Canine Diseases
[description not available]		04.1531
Helminthiasis, Animal
Infestation of animals with parasitic worms of the helminth class. The infestation may be experimental or veterinary.		02.0510
Gagging
Contraction of the muscle of the PHARYNX caused by stimulation of sensory receptors on the SOFT PALATE, by psychic stimuli, or systemically by drugs.		02.0210
Infections, Nematode
[description not available]		03.7721
Ascariasis
Infection by nematodes of the genus ASCARIS. Ingestion of infective eggs causes diarrhea and pneumonitis. Its distribution is more prevalent in areas of poor sanitation and where human feces are used for fertilizer.		02.3620
Necatoriasis
Infection of humans or animals with hookworms of the genus NECATOR. The resulting anemia from this condition is less severe than that from ANCYLOSTOMIASIS.		02.3620
Intestinal Diseases, Parasitic
Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS.		01.9510
Infections, Helicobacter
[description not available]		01.9810
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		01.9810